COVID-19 Vaccinations: Evidence for Delaying-Second-Dose and Mix-and-Match Strategies ?

The debate around delaying second doses and mixing COVID-19 vaccines grew out of urgent pandemic pressures, and the evidence has only recently started to catch up. Early data and modeling work suggested that a strong first-dose response, especially for mRNA vaccines, could meaningfully cut infections and hospitalizations, giving the delayed-dose strategy some credibility. At the same time, interest in mix-and-match schedules has expanded; early studies now point to good safety and striking antibody responses—particularly AstraZeneca-prime followed by Pfizer-boost—yet key comparisons and real-world effectiveness data remain missing. Until those gaps are filled, the strategy holds promise but still needs stronger evidence.